Inhibrx Biosciences
INBX · NASDAQ · Health Care · Biological Products, (No Diagnostic Substances)
Biological Products, (No Diagnostic Substances) company based in La Jolla, Ca.
Example public filing
CEO bought ~$217K
Mark Lappe, CEO at Inhibrx Biosciences, bought ~$217K of Inhibrx Biosciences shares.
- ~$217K
- Approx. value · 2,176 sh @ $99.60
- 736K
- Holds after · shares reported
- Traded
- Sep 25, 2026
- Filed
- Sep 28, 2026
Data as of Oct 13, 2026. A real record from the official source, chosen as the most recent insider trade or, failing that, the most recent filing of another kind; not a recommendation.
On file for INBX, last 12 months
- 5
- Insider filings
- 0
- Congress trades
- 5
- Fund positions
- 0
- Federal contracts
Records OQRO holds, counted by their date; a 13F position is counted once per quarter it is reported.
Insider buying and selling since 2024
Insiders of Inhibrx Biosciences reported 34 open-market purchases and 0 sales since 2024; purchases in 2 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | 5×5 trades | — |
| 2024 | 29×29 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. The amounts, the people and every filing are in OQRO Pro.
See the full picture with OQRO Pro.
10 records for Inhibrx Biosciences in the last 12 months, each linked to its filing. Full histories, the screener, alerts for the companies you follow and Ask OQRO.
Latest disclosures
Secure payment by Stripe. Renews every month until you cancel; cancel anytime from your account. No free trial.
Public previews are free. Full research requires Pro. No free trial.
What this page holds
- Insider trades and planned sales
- Politician trades (House and Senate)
- Fund holdings from 13F filings
- Federal contracts, lobbying and short selling
- Full history and context, with a link to every filing
What OQRO is
OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.
Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.
Questions about Inhibrx Biosciences insider trading
Have Inhibrx Biosciences insiders bought shares recently?
Yes. Insiders of Inhibrx Biosciences (INBX) filed 5 open-market purchases in the last 90 days; the latest was filed on Sep 28, 2026.
How often do Inhibrx Biosciences insiders buy and sell shares?
Since 2024, Inhibrx Biosciences insiders reported 34 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2026.
Do members of Congress trade INBX?
No trade in Inhibrx Biosciences (INBX) was disclosed by a member of Congress in the last 12 months.
When does Inhibrx Biosciences report its next results?
Inhibrx Biosciences's next results are expected on Nov 13, 2026. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
Insiders who traded Inhibrx Biosciences
Other Biological Products, (No Diagnostic Substances) companies
Inhibrx Biosciences is in 1 disclosure basket
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.